News Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX Other stock markets 12:23:16 2024-04-29 EDT			5-day change	1st Jan Change
8.725 ^USD	+3.01%		-2.91%	+168.73%

04-10	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
03-18	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcutis Appoints David Topper as Chief Financial Officer	04-10	GL
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	04-10	CI
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04-05	AQ
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	04-01	AQ
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	03-28	AQ
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	03-17	CI
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	03-11	GL
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	03-11	CI
Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children	03-11	MT
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	03-10	AQ
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	03-10	CI
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	03-10	GL
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	03-09	AQ
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	03-09	GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	03-06	AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03-05	AQ
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering	03-04	MT
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	03-04	GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	03-04	GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	03-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Summary

Filters